Open-label Study to Evaluate Safety of Multiple Courses of IM Alefacept During Treatment of Chronic Plaque Psoriasis
Public ClinicalTrials.gov record NCT00692172. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label, Multi-center Study to Evaluate the Safety and Tolerability of Intramuscular Administration of Alefacept (LFA-3/IgG1 Fusion Protein) in Subjects With Chronic Plaque Psoriasis Who Have Completed Studies C99-717 or C99-712
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
An extension study to evaluate safety and tolerability of up to 3 additional courses of IM alefacept in patients with chronic plaque psoriasis who have been previously treated with 1 or 2 courses of IM alefacept.
Study identification
- NCT ID
- NCT00692172
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 175 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 2001 (Type not available)
- Primary completion
- Nov 2004 (Actual)
- Completion
- Nov 2004 (Actual)
- Last update posted
- Sep 18, 2014
2001 – 2004
United States locations
- U.S. sites
- 19
- U.S. states
- 15
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Hot Springs | Arkansas | 71913 | — |
| Not listed | Fresno | California | 93710 | — |
| Not listed | La Jolla | California | 92037 | — |
| Not listed | Washington D.C. | District of Columbia | 20010 | — |
| Not listed | Jacksonville | Florida | 32204 | — |
| Not listed | Pinellas Park | Florida | 33781 | — |
| Not listed | Newnan | Georgia | 30263 | — |
| Not listed | Chicago | Illinois | 60611 | — |
| Not listed | Kansas City | Kansas | 66160 | — |
| Not listed | Clinton Township | Michigan | 48038 | — |
| Not listed | St Louis | Missouri | 63110 | — |
| Not listed | Omaha | Nebraska | 68131 | — |
| Not listed | Berlin | New Jersey | 08009 | — |
| Not listed | Lake Oswego | Oregon | 79035 | — |
| Not listed | Portland | Oregon | 97210 | — |
| Not listed | Johnston | Rhode Island | 02919 | — |
| Not listed | Goodlettsville | Tennessee | 37072 | — |
| Not listed | Austin | Texas | 78759 | — |
| Not listed | San Antonio | Texas | 78229 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 24 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00692172, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 18, 2014 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00692172 live on ClinicalTrials.gov.